| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T164 |
0-14 |
Sentence |
denotes |
6 Conclusions |
| T165 |
15-153 |
Sentence |
denotes |
The COVID-19 epidemic represents a health emergency that is inevitably affecting the management of a complex disease such as RA [115,116]. |
| T166 |
154-265 |
Sentence |
denotes |
As a chronic autoimmune inflammatory disorder, RA carries a higher infectious risk than the general population. |
| T167 |
266-498 |
Sentence |
denotes |
The use of synthetic and biologic disease-modifying drugs is associated with a potential further increase in the incidence of serious infections, but the poor control of RA disease activity is an even greater infectious risk factor. |
| T168 |
499-596 |
Sentence |
denotes |
Thus, RA patients should be encouraged to continue their treatment even during COVID-19 outbreak. |
| T169 |
597-786 |
Sentence |
denotes |
In our opinion, this strategy is reasonable as it aims to prevent disease flares that can contributes to increase patient burden, disability, poor quality of life, and healthcare use [117]. |
| T170 |
787-1044 |
Sentence |
denotes |
In addition, the discontinuation of ongoing treatments could lead to the need to introduce CS as bridging therapy, which may further increase the risk of viral infection, as well as being inappropriate for the management of SARS-CoV2 interstitial pneumonia. |
| T171 |
1045-1282 |
Sentence |
denotes |
Chloroquine and hydroxychloroquine are currently included in the treatment protocol for the management of COVID-19 infections and might be useful to prevent or mitigate the course of infection in patients with RA taking them as csDMARDs. |
| T172 |
1283-1574 |
Sentence |
denotes |
The use of IL-6 inhibitors as tocilizumab or sarilumab seems to be promising for the management of most critical cases of interstitial pneumonia complicated by CRS, but the identification of definite criteria to discriminate patients to be treated with these compounds is still under debate. |
| T173 |
1575-1808 |
Sentence |
denotes |
Finally, although baricitinib has the potential to affect SARS-CoV2 penetration into pulmonary epithelial cells, major concerns remain about the inhibition of IFNs activity which could be detrimental in the course of viral infection. |
